Biohaven Stock Slides More Than 8% on Drug Trial Failure

Biohaven's (NYSE:BHVN) drug candidate troriluzole failed to meet its primary endpoint in a phase 4 clinical trial, the company said in a press release Monday. Troriluzole was being evaluated for the treatment of generalized anxiety disorder (GAD), but the results showed that it was no more effective than a placebo.